ClinicalTrials.gg
CompletedNCT00343291Updated Jun 7, 2011Results posted

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

A Phase 2 interventional study of Cetuximab and Bevacizumab in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-07.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 2 under way, none of them phase 3. Cetuximab · Carcinoma, Non-Small-Cell Lung.

Enrollment
10th of 51
121 · median 63
Started
2006
with 6 others
Phase 2
31 of 52
1 open now
Registered
24th of 52
by date
Lead sponsor
13 of 52
Eli Lilly and Company

Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2006, is one of 31 in phase 2, and was the 24th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Non-Small Cell Lung Cancer
  • Malignant pleural effusions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has or cytologically confirmed non-small cell lung cancer (NSCLC), except squamous cell carcinoma. Mixed tumors will be categorized by the predominant cell type, but the presence of small cell lung cancer elements will make the patient ineligible. Cytologic or histologic elements can be established on tumor aspirates or .
  • The patient has advanced NSCLC (Stage IIIB with malignant pleural effusion or Stage IV or recurrent disease).
  • Patients must have as defined by (RECIST).
  • The patient's (ECOG) performance status is 0 or 1.
  • The patient has adequate hematologic function as defined by an greater than or equal to 1500/mm³, greater than or equal to 9 gm/dL, and a count greater than or equal to 100,000/mm³ obtained within 2 weeks prior to the first dose of study medication.
  • The patient has adequate hepatic function as defined by a total greater than or equal to 1.5 mg/dL and transaminases and alkaline phosphatase less than or equal to 5 x the (ULN) obtained within 2 weeks prior to the first dose of study medication.
  • The patient has adequate renal function as defined by serum creatinine less than or equal to 1.5 x ULN or calculated (CrCl) >60 mL/minute, and urine dipstick for proteinuria \<1+ (ie, either 0 or trace) obtained within 2 weeks prior to the first dose of study medication. If urine dipstick is greater than or equal to 1+, then a 24-hour urine for protein must demonstrate \<500 mg of protein in 24 hours to allow participation in the study.
  • The patient has adequate coagulation function as defined by less than or equal to 1.5 and a Prothrombin time and partial thromboplastin time less than or equal to ULN obtained within 2 weeks prior to the first dose of study medication.
  • The patient, if a woman of , agrees to use an accepted and effective method of (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study. If a male and sexually active, the patient agrees to use effective contraception.

Exclusion criteria

Exclusion Criteria:

  • The patient has known Central Nervous System . A head computed tomography (CT) is required within 4 weeks prior to the first dose of study medication (magnetic resonance imagines [MRIs] are also acceptable).
  • The patient has received prior cetuximab therapy.
  • The patient has received prior bevacizumab therapy.
  • The patient has received prior systemic chemotherapy or radiation therapy at any time for lung cancer.
  • Any concurrent other than basal cell skin cancer, or carcinoma in situ of the cervix. Patients with adequately treated cancers of other histologies who have been disease-free for more than 3 years prior to the first treatment dose are eligible.
  • Concurrent treatment with other anti-cancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy.
  • The patient has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • The patient has a history of thrombotic or hemorrhagic disorders.
  • The patient has uncontrolled hypertension (>150/100 mmHg) on a standard regimen of anti-hypertensive therapy.
  • The patient is receiving chronic daily treatment with aspirin (>325 mg/day) or nonsteroidal anti-inflammatory agents known to inhibit function.
  • The patient is receiving treatment with dipyridamole (Persantine®), ticlopidine (Ticlid®), clopidogrel (Plavix®) and /or cilostazol (Pletal®).
  • The patient is receiving anti-coagulation therapy. Prophylactic anti-coagulation of venous access devices is allowed. Caution should be taken on treating patients with low dose heparin or low molecular weight heparin for deep vein thrombosis (DVT) prophylaxis during treatment with bevacizumab as there may be an increased risk of bleeding.
  • Patients with a history of gross hemoptysis (defined as bright red blood or greater than or equal to ½ teaspoon).
  • The patient has a serious non-healing wound ulcer, bone fracture, or major surgical procedure within 30 days prior to first dose of study medication.
  • Elective or planned major surgery to be performed during the course of the trial.
  • The patient has a pre-existing neuropathy >grade 1.
  • The patient, if a woman, is pregnant or lactating.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Active comparator
    Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)

    Cycles 1-6: * Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week * Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle * Paclitaxel 200 mg/m² on day 1 of every 3 week cycle * Carboplatin area under curve (AUC=6 min\*mg/mL) on day 1 of every 3 week cycle Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met

    Biological: Cetuximab · Biological: Bevacizumab · Drug: Paclitaxel · Drug: Carboplatin

  • Active comparator
    Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)

    Cycles 1-6: * Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week * Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle Cycles 1-3: * Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles * Carboplatin AUC=6 min\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met

    Biological: Cetuximab · Biological: Bevacizumab · Drug: Paclitaxel · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD ≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.

    Time frame: Randomization to PD or date of death from any cause up to 33.1 months

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as the time from randomization to death. Participants who are alive will be censored on the last known alive date.

    Time frame: Randomization to the date of death from any cause up to 42.7 months

  2. Percentage of Participants Achieving an Objective Overall Response (Overall Response Rate)

    The best objective overall response rate (ORR) is the percentage of randomized participants with a best overall response of complete response (CR) or partial response (PR), as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions. ORR is calculated as a total number of participants with CR or PR divided by the total number of participants treated in that arm, multiplied by 100. Participants with no post-baseline evaluation will be considered as a non-responder.

    Time frame: Randomization to measured progressive disease up to 31.8 months

  3. Duration of Overall Response

    The duration of response, in participants with best overall response of CR or PR, is measured from the date criteria are met for CR/PR (whichever is first recorded), until the first date that the criteria for PD is met or death. CR, PR, and PD, as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions; PD≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.

    Time frame: Time of first response to the first date of PD or death due to any cause up to 31.8 months

  4. Percentage of Participants With Symptomatic Response (Symptom Response Rate)

    Functional Assessment of Cancer Therapy for Patients With Lung Cancer (FACT-L) measures domains of health-related quality of life (HR-QL): physical wellbeing (WB), social/family WB, emotional WB, functional WB, and additional lung cancer concerns. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item Lung cancer subscale (LCS) score maintained for 2 consecutive assessments. Scores range from 0-28 with higher scores indicating fewer symptoms. Patients with a score of \>26 were not evaluable for symptom response, since a score of 28 is the maximum possible.

    Time frame: From date of partial response until progression of disease up to 31.8 months

07

Results

Posted Jun 7, 2011

Participant flow

Participant flow — Overall Study
MilestoneCetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)
Started6061
Received at least one dose of study drug5858
Completed35
Not completed5756
Withdrew: Adverse event1313
Withdrew: Death32
Withdrew: Progressive disease3334
Withdrew: Withdrawal by subject02
Withdrew: Other85

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD ≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.

Time frame:
Randomization to PD or date of death from any cause up to 33.1 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsCetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)
Progression Free Survival (PFS)6.05 (5.65 to 7.03)4.50 (4.01 to 5.42)
SecondaryOverall Survival

Overall survival is defined as the time from randomization to death. Participants who are alive will be censored on the last known alive date.

Time frame:
Randomization to the date of death from any cause up to 42.7 months
Reported as:
Median · months
Overall Survival
monthsCetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)
Overall Survival12.06 (9.40 to 19.25)11.63 (6.64 to 17.61)
SecondaryPercentage of Participants Achieving an Objective Overall Response (Overall Response Rate)

The best objective overall response rate (ORR) is the percentage of randomized participants with a best overall response of complete response (CR) or partial response (PR), as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions. ORR is calculated as a total number of participants with CR or PR divided by the total number of participants treated in that arm, multiplied by 100. Participants with no post-baseline evaluation will be considered as a non-responder.

Time frame:
Randomization to measured progressive disease up to 31.8 months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Objective Overall Response (Overall Response Rate)
percentage of participantsCetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)
Percentage of Participants Achieving an Objective Overall Response (Overall Response Rate)51.7 (39.0 to 64.3)44.3 (31.8 to 56.7)
SecondaryDuration of Overall Response

The duration of response, in participants with best overall response of CR or PR, is measured from the date criteria are met for CR/PR (whichever is first recorded), until the first date that the criteria for PD is met or death. CR, PR, and PD, as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions; PD≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.

Time frame:
Time of first response to the first date of PD or death due to any cause up to 31.8 months
Reported as:
Median · months
Duration of Overall Response
monthsCetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)
Duration of Overall Response4.86 (4.30 to 7.16)3.94 (2.92 to 4.47)
SecondaryPercentage of Participants With Symptomatic Response (Symptom Response Rate)

Functional Assessment of Cancer Therapy for Patients With Lung Cancer (FACT-L) measures domains of health-related quality of life (HR-QL): physical wellbeing (WB), social/family WB, emotional WB, functional WB, and additional lung cancer concerns. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item Lung cancer subscale (LCS) score maintained for 2 consecutive assessments. Scores range from 0-28 with higher scores indicating fewer symptoms. Patients with a score of \>26 were not evaluable for symptom response, since a score of 28 is the maximum possible.

Time frame:
From date of partial response until progression of disease up to 31.8 months
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic Response (Symptom Response Rate)
percentage of participantsCetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)
Percentage of Participants With Symptomatic Response (Symptom Response Rate)41.9 (27.1 to 56.6)38.6 (24.2 to 53.0)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)—38/58 (65.5%)56/58 (96.6%)
Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)—28/58 (48.3%)57/58 (98.3%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventCetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)
PneumoniaInfections and infestations4/585/58
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/585/58
VomitingGastrointestinal disorders4/582/58
Disease progressionGeneral disorders4/583/58
DehydrationMetabolism and nutrition disorders4/582/58
ConstipationGastrointestinal disorders3/580/58
NauseaGastrointestinal disorders3/581/58
PyrexiaGeneral disorders3/580/58
HypersensitivityImmune system disorders1/583/58
Febrile neutropeniaBlood and lymphatic system disorders2/581/58
Most frequent other events
Showing 10 of 92
Most frequent other events
EventCetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)
Dermatitis acneiformSkin and subcutaneous tissue disorders45/5840/58
FatigueGeneral disorders32/5828/58
NauseaGastrointestinal disorders30/5823/58
StomatitisGastrointestinal disorders19/5823/58
ConstipationGastrointestinal disorders22/5816/58
DiarrhoeaGastrointestinal disorders22/5814/58
AlopeciaSkin and subcutaneous tissue disorders21/5822/58
AnaemiaBlood and lymphatic system disorders21/5810/58
HypomagnesaemiaMetabolism and nutrition disorders19/5813/58
Decreased appetiteMetabolism and nutrition disorders17/5818/58

Baseline characteristics

Age Continuous
Age Continuous(years)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)Total
Mean63.4 ± 11.5262.1 ± 8.9762.8 ± 10.29
Age, Customized
Age, Customized(participants)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)Total
< 65 years313263
≥ 65 years292958
Age, Customized
Age, Customized(participants)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)Total
< 70 years415192
≥ 70 years191029
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)Total
Female252752
Male353469
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)Total
White5353106
Black246
Asian123
Hispanic303
Other123
Region of Enrollment
Region of Enrollment(participants)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)Total
United States6061121
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)Total
0 - Full Active242953
1 - Ambulatory, Restricted Strenuous Activity282755
Missing/Unknown8513
Smoking Status
Smoking Status(participants)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)Total
Current171128
Past374481
Exposed to Second-hand Smoke213
Not Exposed to Second-hand Smoke448
Missing/Unknown011
08

Study locations

43 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Decatur, Alabama 35601, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Huntsville, Alabama 35805, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Scottsdale, Arizona 85258, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fountain Valley, California 92708, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Grass Valley, California 95945, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenbrae, California 94904, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orange, California 92868, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fairfield, Connecticut 06824, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hollywood, Florida 33021, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32256, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Port Richey, Florida 34655, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Petersburg, Florida 33705, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, Georgia 30607, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Augusta, Georgia 30901, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60612, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Evanston, Illinois 60201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gurnee, Illinois 60031, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wichita, Kansas 67214, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky 40215, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Metairie, Louisiana 70006, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baltimore, Maryland 21237, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bethesda, Maryland 20817, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kalamazoo, Michigan 49048, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lambertville, Michigan 48144, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lansing, Michigan 48910, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63110, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lincoln, Nebraska 68510, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    High Point, North Carolina 27262, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oklahoma City, Oklahoma 73112, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tulsa, Oklahoma 74136, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Langhorne, Pennsylvania 19047, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19114, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Willow Grove, Pennsylvania 19090, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleston, South Carolina 29403, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hilton Head Island, South Carolina 29926, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    MT Pleasant, South Carolina 29464, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Johnson City, Tennessee 37604, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Grapevine, Texas 76051, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77024, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77030, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tacoma, Washington 98405, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of May 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2006
First posted
Jun 22, 2006
Start
Dec 2006
Primary completionActual
May 2010
CompletionActual
Dec 2010
Results first posted
Jun 7, 2011
Last update
Jun 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00343291
First posted
Jun 22, 2006
Start date
Dec 2006
Primary completion
May 2010
Completion
Dec 2010
Results posted
Jun 7, 2011
Last update
Jun 7, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Bevacizumab · Paclitaxel · Carboplatin

Start the discussion